News for Bio-Techne Corporation (TECH)

We came across a bullish thesis on Bio-Techne Corporation on Stock Analysis Compilation’s Substack. In this article, we will summarize the bulls’ thesis on TECH.

For Q2 of 2025, Aristotle Atlantic’s Focus Growth Composite posted a total return of 17.70% gross of fees (17.67% net of fees). Read more here.

For the second quarter of 2025, Aristotle Atlantic’s Core Equity Composite posted a total return of 14.43% gross of fees (14.30% net of fees). Read more here.

Bio-Techne is expected to report its fiscal fourth-quarter earnings next month, and analysts forecast a modest single-digit decrease in its bottom line.

PR NewswireMINNEAPOLIS, July 17, 2025 MINNEAPOLIS, July 17, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will

Bio-Techne (TECH) schedules Q4 and fiscal 2025 financial results conference call for August 6, 2025. The webcast will be available on Bio-Techne's inves

Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, is pleased to announce a strategic distribution partnership wi

Headwaters Capital Management, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The portfolio bounced back from the first quarter uncertainty and, like the rest of the market, experienced a strong rebound after the tariff-induced sell-off at the start of the quarter. The portfolio gained […]

PR NewswireMINNEAPOLIS, July 14, 2025 MINNEAPOLIS, July 14, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple West

Bio-Techne's Simple Westernâ„¢ Technology crucial in FDA's approval of ZEVASKYNâ„¢, a pioneering cell-based gene therapy. Chosen for superior capabiliti

Bio-Techne has underperformed the Nasdaq over the past year, but analysts are moderately optimistic about the stock’s prospects.

Bio-Techne appears overvalued despite strong revenue growth, solid debt coverage, and looming U.S. healthcare funding cuts. Find out why TECH stock is a hold.

Baron Funds, an investment management company, released its “Baron Asset Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. After a strong start to 2025, U.S.

PR NewswireST. PAUL, Minn., June 10, 2025 ST. PAUL, Minn., June 10, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-T

Immuneel Therapeutics has been awarded a $150,000 G-Rex Grant to enhance CAR-T cell manufacturing in India. The grant aims to improve the scalability an

The stock market opened with strong momentum on Sunday, June 8, 2025, as investors continued to digest Friday's better-than-expected jobs report. At the

Bio-Techne faces significant macro and policy headwinds, including reduced academic research funding, China risks, and U.S. healthcare reforms. Learn more on TECH stock here.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

We came across a bullish thesis on Bio-Techne Corporation (TECH) on scuttleblurb’s Substack. In this article, we will summarize the bulls’ thesis on TECH.